Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing
Authors:
- 10 September 2021
- Vol. 54 (1) , 55-62
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK FusionsAmerican Journal of Surgical Pathology, 2017
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Cancer Discovery, 2017
- Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumornpj Precision Oncology, 2017
- A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastomaCNS Oncology, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade gliomaNature Genetics, 2014
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Trk A, B, and C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendrogliomaActa Neuropathologica, 1998